| Literature DB >> 25449777 |
Yosuke Togashi1, Akihiro Kogita2, Hiroki Sakamoto3, Hidetoshi Hayashi1, Masato Terashima1, Marco A de Velasco1, Kazuko Sakai1, Yoshihiko Fujita1, Shuta Tomida1, Masayuki Kitano3, Kiyotaka Okuno4, Masatoshi Kudo3, Kazuto Nishio5.
Abstract
We previously reported that activin produces a signal with a tumor suppressive role in pancreatic cancer (PC). Here, the association between plasma activin A and survival in patients with advanced PC was investigated. Contrary to our expectations, however, patients with high plasma activin A levels had a significantly shorter survival period than those with low levels (median survival, 314 days vs. 482 days, P = 0.034). The cellular growth of the MIA PaCa-2 cell line was greatly enhanced by activin A via non-SMAD pathways. The cellular growth and colony formation of an INHBA (beta subunit of inhibin)-overexpressed cell line were also enhanced. In a xenograft study, INHBA-overexpressed cells tended to result in a larger tumor volume, compared with a control. The bodyweights of mice inoculated with INHBA-overexpressed cells decreased dramatically, and these mice all died at an early stage, suggesting the occurrence of activin-induced cachexia. Our findings indicated that the activin signal can promote cancer progression in a subset of PC and might be involved in cachexia. The activin signal might be a novel target for the treatment of PC.Entities:
Keywords: Activin signal; Cachexia; INHBA; INHBB; Pancreatic cancer
Mesh:
Substances:
Year: 2014 PMID: 25449777 DOI: 10.1016/j.canlet.2014.10.037
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679